EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience

Simona Malucchi iD, Marco De Gobbi iD, Maria Malentacchi, Stefano Ulisciani, Caterina Ascenzi, Antonio Bertolotto iD, Alessia Di Sapio iD

Multiple Sclerosis Journal – Experimental, Translational and Clinical · 2026-04 · 12 (2)

DOI: 10.1177/20552173261437600 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Multiple Sclerosis Journal – Experimental, Translational and Clinical, online erschienen am 25.06.2026. Verfasst von Simona Malucchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Regional Multiple Sclerosis Referral Center, University Hospital San Luigi Gonzaga, Orbassano, Turin, Italy. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Autologous haematopoietic stem cell transplantation (AHSCT) is a potential therapeutic strategy for patients with relapsing multiple sclerosis (pwRMS) unresponsive to disease-modifying therapies (DMTs), though its optimal position in the treatment algorithm remains undefined.

Objective

To describe treatment outcomes of 30 AHSCT performed in 29 pwRMS.

Methods

Retrospective single-centre real-world study. Patients underwent AHSCT between 2001 and 2025. Median age at disease onset, diagnosis, and AHSCT was 21, 23, and 32 years, respectively. Mean EDSS at AHSCT was 3.1 (range 1.0–9.0). Median follow-up was 8 years (range 0.5–20.6). Carmustine, etoposide, cytarabine, melphalan (BEAM) + anti-thymocyte globulin (ATG) was the most used high-dose chemotherapy regimen. Brain magnetic resonance imaging was performed at 6 months, 12 months, and then annually after AHSCT.

Results

In patients with at least 6 months of follow-up, no evidence of disease activity-3 (NEDA-3) status was present in 16 out of 27 (59.2%); evidence of disease activity appeared after a median time of 33 months (range 5–74). NEDA-3 was maintained in 75% of the BEAM + ATG subgroup at the last follow-up. In the whole cohort, the mortality rate was 0%.

Conclusions

AHSCT is a highly efficacious option for patients with hyperaggressive onset or highly active disease despite the high efficacy of DMTs.

Schlagwörter

Stichwörter der Autor:innen

Autologous haematopoietic stem cell transplantationhigh efficacy disease-modifying therapies (HE-DMTs)high-dose immunosuppressive regimenmultiple sclerosisno evidence of disease activity-3 (NEDA-3)

Autor:innen und Institutionen

  • Department of Neurology and Regional Multiple Sclerosis Referral Center, University Hospital San Luigi Gonzaga, Orbassano, Turin, Italy.
  • Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy.
  • Subintensive Oncohaematology and Bone Marrow Transplant Center, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy.
  • University Hospital San Luigi Gonzaga, Neuroscience Institute Cavalieri Ottolenghi (NICO), Turin, ItalyKoelliker Hospital, Turin, Italy.

ORCID-Profile: Simona Malucchi, Marco De Gobbi, Antonio Bertolotto, Alessia Di Sapio

Zitieren

APA

Malucchi, S., De Gobbi, M., Malentacchi, M., Ulisciani, S., Ascenzi, C., Bertolotto, A., & Di Sapio, A. (2026). Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 12(2). https://doi.org/10.1177/20552173261437600

Vancouver

Malucchi S, De Gobbi M, Malentacchi M, Ulisciani S, Ascenzi C, Bertolotto A, et al. Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience. Multiple Sclerosis Journal – Experimental, Translational and Clinical. 2026;12(2). doi:10.1177/20552173261437600

BibTeX
@article{Malucchi2026,
  author = {Malucchi, Simona and De Gobbi, Marco and Malentacchi, Maria and Ulisciani, Stefano and Ascenzi, Caterina and Bertolotto, Antonio and Di Sapio, Alessia},
  title = {Long-term outcomes of autologous haematopoietic stem cell transplantation in multiple sclerosis: A retrospective single-centre experience},
  journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
  year = {2026},
  volume = {12},
  number = {2},
  doi = {10.1177/20552173261437600}
}
Kostenlos starten →